

Table S1. Characteristics of infection in patients with hVISA bacteremia according to definitive treatment regimen

Characteristic	Definitive linezolid	Definitive glycopeptide	<i>P</i>
	therapy (n = 32)	therapy (n = 89)	
Metastatic infection	10 (31.3)	16 (18.0)	0.117
Infective endocarditis ^a	6 (18.8)	6 (6.7)	0.080
Catheter-related infection	17 (53.1)	42 (47.2)	0.565
Pneumonia	3 (9.4)	8 (9.0)	0.999
Skin and soft tissue infection	1 (3.1)	5 (5.6)	0.999
Bone and joint infection	3 (9.4)	3 (9.4)	0.188
Post-operative wound infection	1 (3.1)	8 (9.0)	0.442
Primary bacteremia	2 (6.3)	11 (12.4)	0.510

Data are presented as number (%).

^a Six patients who had had persistent bacteremia despite adequate vancomycin trough level (15-20 mg/L) were treated with linezolid. Of these patients, 5 patients were successfully treated with linezolid.